Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Recombinant Protein Therapeutics CDMO Market

Recombinant Protein Therapeutics CDMO Market Trends

Report ID: GMI8819
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Recombinant Protein Therapeutics CDMO Market Trends

Biologics are becoming increasingly favored in the pharmaceutical industry due to their high specificity, efficacy, and reduced side effects compared to traditional small-molecule drugs. This preference is particularly evident in the treatment of chronic diseases such as cancer, autoimmune disorders, and diabetes, where biologics offer targeted therapeutic approaches.
For instance, as per the International Diabetes Federation, in 2021 around 537 million people lived with diabetes all over the world. Further, the number of diabetic patients is expected to reach 643 million and 783 million by 2030 and 2045 respectively.
As the prevalence of these chronic conditions continues to rise globally, there is a growing demand for innovative biologic therapies. This surge in demand directly translates to increased manufacturing needs for recombinant protein therapeutics, driving growth in the CDMO market.
Furthermore, with increasing demand for biologics the biopharmaceutical industries reliance on CDMOs for biologics outsourcing is expected to grow, further driving the demand for recombinant protein therapeutics CDMOs, thereby boosting the overall market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Recombinant protein therapeutics CDMO market size was USD 21 billion in 2023 and is expected to register 14% CAGR from 2024-2032 owing to Increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders worldwide.

Recombinant protein therapeutics CDMO industry from the mammalian segment recorded over 61.5% share in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to being preferred to produce complex protein therapeutics such as cytokines and growth factors.

North America recombinant protein therapeutics CDMO industry reached USD 8.5 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to access to advanced technologies, state-of-the-art infrastructure, and cutting-edge research capabilities in the region.

Batavia Biosciences B.V., BIOVIAN, Catalent, Inc, Curia Global, Inc., Enzene Biosciences Ltd, FUJIFILM Diosynth Biotechnologies, HALIX B.V., Lonza, Richter-Helm BioLogics, and WuXi Biologics, are some of the major Recombinant Protein Therapeutics CDMO companies worldwide.